Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2012 Aug 16;14(4):R119.
doi: 10.1186/bcr3244.

Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain

Renata Duchnowska, Rafał Dziadziuszko, Tomasz Trojanowski, Tomasz Mandat, Waldemar Och, Bogumiła Czartoryska-Arłukowicz, Barbara Radecka, Wojciech Olszewski, Franciszek Szubstarski, Wojciech Kozłowski, Bożena Jarosz, Wojciech Rogowski, Anna Kowalczyk, Janusz Limon, Wojciech Biernat, Jacek Jassem; Polish Brain Metastasis Consortium
Multicenter Study

Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain

Renata Duchnowska et al. Breast Cancer Res. .

Abstract

Introduction: We investigated the status of estrogen receptor alpha (ERα), progesterone receptor (PR), and epidermal growth factor receptor 2 (HER2) in primary tumor and in the corresponding brain metastases in a consecutive series of breast cancer patients. Additionally, we studied factors potentially influencing conversion and evaluated its association with survival.

Methods: The study group included 120 breast cancer patients. ERα, PR, and HER2 status in primary tumors and in matched brain metastases was determined centrally by immunohistochemistry and/or fluorescence in situ hybridization.

Results: Using the Allred score of ≥ 3 as a threshold, conversion of ERα and PR in brain metastases occurred in 29% of cases for both receptors, mostly from positive to negative. Conversion of HER2 occurred in 14% of patients and was more balanced either way. Time to brain relapse and the use of chemotherapy or trastuzumab did not influence conversion, whereas endocrine therapy induced conversion of ERα (P = 0.021) and PR (P = 0.001), mainly towards their loss. Receptor conversion had no significant impact on survival.

Conclusions: Receptor conversion, particularly loss of hormone receptors, is a common event in brain metastases from breast cancer, and endocrine therapy may increase its incidence. Receptor conversion does not significantly affect survival.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Phenotypes for ER (A), PR (B), and HER2 (C) in primary tumors and their matched brain metastases. ER, estrogen receptor; PR, progesterone receptor; HER2, epidermal growth factor receptor 2.
Figure 2
Figure 2
Overall survival in relation to ERα conversions. Log-rank P = 0.041 (all comparisons); P = 0.005 (ER-/ER- versus others); HR = 1.84 (1.20 to 2.83; ER-/ER- versus others).
Figure 3
Figure 3
Overall survival in relation to progesterone receptor (PR) conversions. Log-rank P = 0.037 (all comparisons); P = 0.005 (PR-/PR- versus others); HR = 1.89 (1.22 to 2.94; PR-/PR- versus others).
Figure 4
Figure 4
Overall survival in relation to epidermal growth factor receptor 2 (HER2) conversions. Log-rank P = 0.944 (all comparisons); P = 0.582 (PR-/PR- versus others); HR = 1.13 (0.73 to 1.74; HER2-/HER2- versus others).
See this image and copyright information in PMC

References

    1. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol. 2004;14:3608–3617. doi: 10.1200/JCO.2004.01.175. - DOI - PubMed
    1. Pestalozzi BC, Zahrieh D, Price KN, Holmberg SB, Lindtner J, Collins J, Crivellari D, Fey MF, Murray E, Pagani O, Simoncini E, Castiglione-Gertsch M, Gelber RD, Coates AS, Goldhirsch A. International Breast Cancer Study Group (IBCSG): identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG) Ann Oncol. 2006;14:935–944. doi: 10.1093/annonc/mdl064. - DOI - PubMed
    1. Harrell JC, Prat A, Parker JS, Fan C, He X, Carey L, Anders C, Ewend M, Perou CM. Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse. Breast Cancer Res Treat. 2012;14:523–535. doi: 10.1007/s10549-011-1619-7. - DOI - PMC - PubMed
    1. Gaedcke J, Traub F, Milde S, Wilkens L, Stan A, Ostertag H, Christgen M, von Wasielewski R, Kreipe HH. Predominance of the basal type and HER-2/neu type in brain metastasis from breast cancer. Modern Pathol. 2007;14:864–870. doi: 10.1038/modpathol.3800830. - DOI - PubMed
    1. Crivellari D, Pagani O, Veronesi A, Lombardi D, Nolè F, Thürlimann B, Hess D, Borner M, Bauer J, Martinelli G, Graffeo R, Sessa C, Goldhirsch A. International Breast Cancer Study Group. High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Ann Oncol. 2001;14:353–356. doi: 10.1023/A:1011132609055. - DOI - PubMed

Publication types

MeSH terms